PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biogen Pharmachem reported a net loss of Rs. 49.15 lakhs for Q2 FY26 (ended 30 Sep 2025), swinging from a profit of Rs. 134.48 lakhs in Q2 FY25. For H1 FY26, the loss widened to Rs. 99.73 lakhs versus a profit of Rs. 85.33 lakhs in H1 FY25. Revenue from operations remains nil across all periods — the company has no core business income, and other income has turned negative at Rs. (10.49) lakhs in Q2 FY26 versus Rs. 154.28 lakhs a year ago. The company raised Rs. 630 lakhs via preferential warrants during the half year, lifting share capital from Rs. 6,526.03 lakhs to Rs. 9,026.03 lakhs. Equity reserves have dropped sharply from Rs. 2,666.74 lakhs (Mar 25) to Rs. 882.07 lakhs (Sep 25), reflecting accumulated losses. Auditor Rishi Sekhri and Associates issued an unqualified review report.
The company is loss-making with no operational revenue, sustained only by investment/other income which has now turned negative, eroding equity reserves. Continued losses and lack of a core revenue stream are red flags for shareholders.